Question explored with the scientific record
Does shingles vaccination decrease dementia risk
The short version: the evidence that shingles vaccination cuts dementia risk is a statistical signal from observational studies, not a proven effect, and the mechanism is speculative.
The only direct evidence on this question is a single 2025 meta-analysis of six observational studies [14]. It found a pooled 32% relative reduction in dementia among vaccinated people (RR 0.68, 95% CI 0.56–0.83). That sounds big, but the heterogeneity was extreme (I² = 99%), meaning the studies disagree with each other so much that averaging them is questionable. When the authors removed studies that did not adjust for confounders, the effect shrank. Observational studies comparing vaccinated to unvaccinated people are vulnerable to the healthy-user bias: people who get one vaccine are more likely to exercise, eat well, and see a doctor regularly—all of which lower dementia risk independently.
The rest of the retrieved evidence is about preventing shingles, not dementia. The ZOE trials [10] showed Shingrix prevents shingles with 90–97% efficacy, but those trials did not measure dementia. The 2025 Delphi consensus [12] listed the shingles vaccine as a candidate for repurposing against Alzheimer's, but that is expert opinion, not data.
| Comparison | Effect on dementia | What the evidence actually is |
|---|---|---|
| Vaccinated vs unvaccinated (6 observational studies) | 32% relative reduction [14] | High heterogeneity, healthy-user bias not ruled out |
| Shingrix vs placebo (ZOE trials) | Not measured | No dementia endpoint in the trials |
| Antiviral treatment vs none (4 studies) | 16% relative reduction [14] | Also observational, also heterogeneous |
The mechanism—that preventing shingles reduces neuroinflammation—is plausible but unproven. Shingles itself is associated with a small increase in dementia risk (RR 1.14) [14], so preventing it could in theory lower that risk. But the vaccine's adjuvant (AS01B) is a potent immune stimulant [7], and chronic immune activation is itself a risk factor for neurodegeneration. Which direction the net effect goes is unknown.
My call: the evidence is too weak and too conflicted to conclude that shingles vaccination reduces dementia risk. The signal is worth studying in a proper randomized trial, but no such trial exists. Confidence: low.
Sources used 14
-
Which patients should receive the herpes zoster vaccine?
This clinical pharmacology review summarizes the efficacy, safety, dosing, and administration of the recombinant zoster vaccine (RZV/Shingrix) for herpes zoster prevention, supporting its preference over zoster vaccine live (ZVL/Zostavax) in immunocompetent adults.
DOI: 10.1097/01.jaa.0000578788.69674.2b -
Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status
This study evaluates the effectiveness of the herpes zoster vaccine in preventing herpes zoster and its associated pain, finding a significant reduction in incidence and symptoms among vaccinated individuals aged 60 and older.
DOI: 10.1080/21645515.2015.1016681 -
Herpes zoster and vaccination: A clinical review
This clinical review evaluates the effectiveness of the herpes zoster vaccine in preventing herpes zoster and its complications, highlighting its cost-effectiveness particularly in individuals aged 70 and older, while also addressing issues related to insurance coverage.
DOI: 10.2146/ajhp090118 -
Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease
In a real-world Kaiser Permanente Southern California cohort of adults aged ≥50 with inflammatory bowel disease (IBD), two doses of recombinant zoster vaccine (RZV) significantly reduced herpes zoster incidence by about 65% without increasing short-term IBD flare risk, supportin…
DOI: 10.1080/21645515.2025.2576981 -
Improving herpes zoster vaccine rates: The impact of a targeted educational program
This study identifies barriers faced by nurse practitioners in administering the herpes zoster vaccine and evaluates the effectiveness of a targeted educational program designed to improve vaccination rates among older adults.
DOI: 10.1097/JXX.0000000000000039 -
Vaccination Coverage in Adult Patients with Inflammatory Bowel Disease: Impact of a Tailored Vaccination Pathway Including COVID-19 and Herpes Zoster in a University Hospital Vaccination Center
A single-center, observational study at the University Hospital Vaccination Center in Messina, Italy, showing that a tailored, multidisciplinary vaccination pathway for adults with inflammatory bowel disease substantially improved vaccination coverage for influenza, pneumococcal…
DOI: 10.3390/vaccines13090961 -
Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine
A comprehensive review detailing how the Shingrix recombinant gE herpes zoster vaccine, with the AS01_B adjuvant, elicits robust humoral and polyfunctional CD4+ T cell responses, achieving high and durable protection against herpes zoster across older adults and various immunoco…
DOI: 10.1016/j.coi.2019.02.009 -
The Epidemiological, Clinical, and Pathological Rationale for the Herpes Zoster Vaccine
This study provides a comprehensive overview of the epidemiology, clinical implications, and the rationale for the herpes zoster vaccine, emphasizing the increasing incidence of herpes zoster (HZ) and postherpetic neuralgia (PHN) in older adults and the need for effective preven…
DOI: 10.1086/522152 -
Efficacy, Effectiveness, and Safety of Herpes Zoster Vaccine in Immunocompromised Patients
A literature review assessing the efficacy, effectiveness, and safety of herpes zoster vaccines (ZVL and RZV) in immunocompromised adults, finding RZV generally effective and safe while ZVL shows variable protection and is often limited to specific milder immunosuppression scena…
DOI: 10.52533/johs.2023.31008 -
Herpes zoster subunit vaccine for the prevention of herpes zoster
This study reviews the efficacy and safety of the herpes zoster subunit vaccine (HZ/su vaccine) in preventing herpes zoster and postherpetic neuralgia in adults aged 50 and older, highlighting its superior efficacy compared to the live attenuated vaccine.
DOI: 10.2146/ajhp170399 -
Herpes zoster vaccination efficacy in the long-term care facility population: a qualitative systematic review
A qualitative systematic review synthesizing evidence on herpes zoster vaccination efficacy in adults over 60 residing in long-term care facilities, finding overall vaccine efficacy and safety signals across LTCF and community settings, but noting limited LTCF-specific data and …
DOI: 10.1080/03007995.2019.1600482 -
Drug repurposing for Alzheimer’s disease: a Delphi consensus and stakeholder consultation
A Delphi consensus plus stakeholder consultation identified three priority drug repurposing candidates for Alzheimer's disease—the herpes zoster vaccine, riluzole, and sildenafil—and outlined a pragmatic, remote/hybrid clinical-trial pathway through the PROTECT platform to accel…
DOI: 10.1186/s13195-025-01895-4 -
Herpes zoster vaccine live: A 10 year review of post-marketing safety experience
This study provides a comprehensive review of the post-marketing safety experience of the herpes zoster vaccine (ZVL) over a 10-year period, analyzing over 23,000 adverse experience reports and confirming a favorable safety profile consistent with clinical trial data.
DOI: 10.1016/j.vaccine.2017.11.013 -
Effects of herpes zoster infection, antivirals and vaccination on risk of developing dementia: A systematic review and meta-analysis
This systematic review and meta-analysis evaluated whether herpes zoster infection affects dementia risk and whether antiviral treatment or vaccination mitigates that risk, finding a small increased risk after infection and protective effects from antivirals and vaccination amid…
DOI: 10.1080/21645515.2025.2546741